middle.news

Tryp Secures $6.1m to Accelerate Psilocin Drug Trials for Binge Eating Disorder

9:47am on Wednesday 5th of November, 2025 AEDT Biotechnology
Read Story

Tryp Secures $6.1m to Accelerate Psilocin Drug Trials for Binge Eating Disorder

9:47am on Wednesday 5th of November, 2025 AEDT
Key Points
  • Raised $6.1 million via placement at $0.034 per share
  • Strong backing from co-founder Dr William Garner and board members
  • Funds to accelerate clinical trials including a world-first binge eating disorder study
  • Advances planned in drug manufacturing and regulatory engagement
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about TYP
OPEN ARTICLE